Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNX-2401 in Metastatic Melanoma with Intracranial and/or Extracranial Lesions
NCT07444606Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2026
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of Ad5-D24RGD in melanoma (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and Adverse Events at 1 year. Started Sep 2026; status: recruiting.
02
Drugs
Ad5-D24RGD
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT07444606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07444606.